Protection after two doses of measles vaccine is independent of interval between doses

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 187-190

  De Serres, Gaston ^a,c   Sciberras, Jill ^b   Naus, Monika ^b   Boulianne, Nicole ^d   Duval, Bernard ^d   Rochette, Louis ^d  

^a UNIVERSITÉ LAVAL   (Canada)

^b ONTARIO MINISTRY OF HEALTH AND LONG TERM CARE   (Canada)

^c Centre de Recherche de la Direction Régionale de la Santé Publique   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE;

ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; PRIORITY JOURNAL; PROPHYLAXIS; PROTECTION;

CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; HUMANS; INFANT; MEASLES; MEASLES VACCINE; ONTARIO; TIME FACTORS;

EID: 0032977336     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314847     Document Type: Article

References (13)

1. Markowitz LE, Katz SL. Measles vaccine: In: Plotkin SA, Mortimer EA, eds. Vaccines, Philadelphia: WB Saunders, 1994:229-76.
2. Peltola H, Heinonen OP, Valle M, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. N Engl J Med 1994;331:1397-402.
3. National Advisory Committee on Immunization. Guidelines for measles control in Canada. Can Dis Wkly Rep 1991;17:35-40.
4. Gans HA, Arvin AM, Galinus J, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998;280:527-32.
5. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, Mumps, and Rubella - Vaccine Use and Strategies for Eliminations of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1998;47:1-57.
6. Supplementary statement on measles elimination in Canada. Can Commun Dis Rep 1996;22:9-15
7. Black FL, Berman LL, Libel M, et al. Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination. Bull World Health Organ 1984;62:315-9.
8. Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr 1979;94: 865-9.
9. Linnemann CC, Dine MS, Roselle GA, et al. Measles immunity after revaccination: results in children vaccinated before 10 months of age. Pediatrics 1982;69:332-5.
10. Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics 1986;77:471-6.
11. Markowitz L, Albrecht P, Orenstein WA, et al. Persistence of measles anti-body after revaccination. J Infect Dis 1992;166:205-8.
12. Ward BJ, Boulianne N, Ratnam S, et al. Cellular Immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 1995;172:1591-5.
13. Paunio M, Peltola H, Valle M, Davidkin I, Virtanen M, Heinonen O. Twice vaccinated recipients are better protected against epidemic measles than are single dose recipients of measles containing vaccin. J Epidemiol Commun Health 1999;53:173-75.